NeoMed is founded on the principles of patient safety and evidence based clinical outcomes. As a strong advocate of patient safety, we have supported the ISO 80369-3 standard for many years and have been instrumental in developing a low dose syringe tip design that has been accepted by GEDSA members. We support a common connector standard which benefits all end users by providing uniform enteral access across all heath provider networks.
ISMP issued a Medical Safety Alert in April that states:
“We fear that the development of a second (and noncompatible) syringe will bring confusion to health systems and possible inventory disruptions at a time when hospitals have been preparing for a transition to ENFit syringes and feeding tubes. This transition must occur soon in California health systems. A California law requires that, as of July 1, 2016, health systems in the state are not permitted to use enteral devices that connect with unrelated systems (e.g., a Luer). Availability of ENFit syringes is imminent. The BD action is counter to what we had hoped would happen—a single, new enteral system to prevent catheter mix-ups with vascular lines. While either of the new devices will accomplish this, it is also predictable that there will be compatibility problems when patients transfer from one healthcare provider to another, or when they are admitted to a hospital with an existing enteral feeding system different than that used by the hospital.”
NeoMed’s innovative family of neonatal, pediatric, and pharmacy ENFit products supports GEDSA and the worldwide ENFit initiative. Our products and transition programs embrace and enhance our legacy, providing products to help improve clinical outcomes, minimize process changes, and help meet cost containment objectives. NeoMed plans to have our NeoConnect NICU and Pharmacy products and accessories available by the California deadline, pending FDA 510(k) clearance.
NM-WEB-007 Rev 0